Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein-producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

被引：0
|
作者：
Wang, Yakun
Wang, Chang
Chen, Xiaofeng
Peng, Zhi
Gu, Yanhong
Wang, Yizhuo
Wang, Xicheng
Li, Jian
Gong, Jifang
Qi, Changsong
Yuan, Jiajia
Lu, Zhihao
Lu, Ming
Shen, Lin
Cao, Yanshuo
Zhang, Xiaotian
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Canc Ctr, Changchun, Jilin, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Oncol Dept, Nanjing, Jiangsu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Early Drug Dev Ctr, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Early Drug Dev Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-244-3829; 283-9769-3573-426; 261-492-3532-2370-7650-2700; 3282-270-434-6184; 261-492-3532-2370-5109; 261-492-2769; 261-566-11347; 4; 3; 2; 3599; 239; 2950; 2425; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [21] Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.
    Zhang, W.
    You, R.
    Zou, X.
    Wang, Z.
    Ouyang, Y-F.
    Liu, Y-L.
    Peng, L.
    You-Ping, L.
    Duan, C-Y.
    Yang, Q.
    Lin, C.
    Yulong, X.
    Chen, S-Y.
    Gu, C-M.
    Huang, P. Y.
    Hua, Y.
    Chen, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S846 - S846
  • [22] First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104)
    Kawazoe, Akihito
    Hashimoto, Tadayoshi
    Itahashi, Kota
    Irie, Takuma
    Ono, Hiromi
    Tamura, Hitomi
    Hongo, Kyoko
    Ikeno, Takashi
    Wakabayashi, Masashi
    Sato, Akihiro
    Nakamura, Yoshiaki
    Fujisawa, Takao
    Nakayama, Izuma
    Koyama, Shohei
    Yoshino, Takayuki
    Nishikawa, Hiroyoshi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study
    Zhichao Jiang
    Aiping Zhou
    Yongkun Sun
    Wen Zhang
    BMC Cancer, 22
  • [24] Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study
    Jiang, Zhichao
    Zhou, Aiping
    Sun, Yongkun
    Zhang, Wen
    BMC CANCER, 2022, 22 (01)
  • [25] First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial
    Zhu Liangjun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial
    Wei, Jia
    Lu, Xiaofeng
    Liu, Qin
    Fu, Yao
    Liu, Song
    Li, Lin
    Liu, Fangcen
    Fan, Xiangshan
    Yang, Ju
    Yang, Yang
    Zhao, Yang
    Guan, Wenxian
    Liu, Baorui
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2007 - 2015
  • [27] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, Shengxiang
    He, Jianxing
    Fang, Yong
    Chen, Gongyan
    Ma, Zhiyong
    Chen, Jianhua
    Guo, Renhua
    Lin, Xiaoyan
    Yao, Yu
    Wu, Gang
    Wang, Quanren
    Zhou, Caicun
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
  • [28] Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study
    Zhang, Xin
    Huo, Haoran
    Nie, Yanan
    Xue, Jiadong
    Yuan, Zengjiang
    Zhang, Zhenyi
    JOURNAL OF GASTRIC CANCER, 2022, 22 (04) : 408 - 417
  • [29] Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial
    Ming Liu
    Guihuan Qiu
    Wenhui Guan
    Xiaohong Xie
    Xinqing Lin
    Zhanhong Xie
    Jiexia Zhang
    Yinyin Qin
    Haijian Du
    Xin Chen
    Yu Deng
    Shiyue Li
    Nanshan Zhong
    Chengzhi Zhou
    Signal Transduction and Targeted Therapy, 10 (1)
  • [30] Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma The CAP 03 Phase 2 Nonrandomized Clinical Trial
    Mao, Lili
    Lian, Bin
    Li, Caili
    Bai, Xue
    Zhou, Li
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Wang, Xuan
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Kong, Yan
    Dai, Jie
    Wei, Xiaoting
    Li, Juan
    Duan, Rong
    Xu, Huayan
    Wu, Xiaowen
    Yang, Yue
    Cheng, Fengzhuo
    Zhang, Cheng
    Xia, Fangzhou
    Pang, Zheng
    Guo, Jun
    Si, Lu
    JAMA ONCOLOGY, 2023, 9 (08) : 1099 - 1107
12345